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ABSTRACT 
Aim: The aim of this systematic review was to determine if the human colon, through the lower gut-liver axis, drives PSC activity by 
assessing the progression of the disease in patients with and without colectomy for colonic disease. 
Background: The gut-liver axis is involved in the pathogenesis of liver disease. Abnormal immune-mediated responses to intestinal 
microbiome are implicated in primary sclerosing cholangitis (PSC) however the mechanisms remain poorly understood. Currently, no 
single animal model recapitulates all attributes of PSC in humans and this limits further studies of gut-liver interactions.  
Methods: A systematic search of PubMed, Medline, and Scopus was performed for articles that contained the terms “colectomy” or 
“bowel resection” AND “primary sclerosing cholangitis” up to 15th April 2018. Articles were reviewed by 2 reviewers and raw data 
collated. A Forest plot was used to illustrate the effect of colectomy on subsequent liver transplantation for PSC. Linear regression was 
used to estimate mortality risk.  
Results: Colectomy appeared to have no effect on PSC progression, although high-quality studies were lacking. Rates of liver 
transplantation or transjugular intrahepatic portosystemic shunt for PSC were not affected by colectomy (OR 0.59, 95% CI 0.14 - 2.53, 
p=0.48). Mortality risk following colectomy in patients with PSC is 2.11% per year (95% CI 0.03% - 4.18%, p=0.032, R2 = 0.722).  
Conclusion: Current evidence is limited but suggests colectomy does not affect the progression of PSC in patients with colonic disease. 
Pathogenic micro-organisms or antigens that drive PSC may not be limited to the lower gut. 
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Introduction  
  1 The gut-liver axis, a concept thought to be first 
introduced in 1987 by Volta et al (1-2), describes the 
complex interactions between the gut microbiome, the 
small and large bowel, the immune system and the liver. 
Recent advances in gastroenterology have implicated the 
gut-liver axis in alcoholic liver disease, non-alcoholic 
fatty liver disease, primary biliary cholangitis, and 
primary sclerosing cholangitis (PSC) (3). In PSC, 
immune-mediated processes lead to chronic 
inflammation of both intra-hepatic and extra-hepatic bile 
ducts, eventually causing liver cirrhosis. Approximately 
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47-76% of patients with PSC also suffer from 
inflammatory bowel disease (IBD) (4), however, a 
causal link has not been established. Dysbiosis in the gut 
microbiome, increased intestinal permeability, 
translocation of circulating pro-inflammatory cytokines 
in the portal vein, and circulating auto-antibodies are 
hallmark characteristics in the pathophysiology of PSC 
(3), however little else is known about the triggering 
microorganism, relevant antigens, or its location within 
the gastrointestinal tract.  
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The role of the colon in the pathogenesis of PSC has long 
served as a controversial point of debate. Early small 
sample sized case series (5-7) have previously reported 
impressive rates of improvement in PSC for patients 
who had undergone colectomy for concomitant 
ulcerative colitis (UC). However, such results were 
irreproducible in larger cohort studies of UC patients (8-
9). In support of gut involvement in PSC, basic science 
research has elucidated the recruitment and preferential 
binding of chemokine (C-C motif) receptor 9 positive - 
integrin α4β7 positive (CCR9+ α4β7+) T-lymphocytes to 
abnormally upregulated mucosal vascular addressin cell 
adhesion molecule 1 (MAdCAM-1), vascular adhesion 
protein-1 (VAP-1) and gut homing chemokine (C-C 
motif) ligand (CCL25) on hepatic endothelial cells, and 
the up-regulation of toll-like receptors on biliary 
epithelial cells and T-Helper type 17 (TH17) cells as 
responses of the gut-liver axis specific to PSC (10-13). 
Clinically, a retrospective study from a transplant centre 
has also demonstrated that colectomy conferred a 
protective effect to liver grafts against recurrent PSC 
(14). Such conflicting reports in literature preclude any 
strong conclusions from being made.  
In looking at animal models to understand the role of the 
colon in the pathogenesis of PSC, current disease models 
of PSC remain sub-optimal and not a single animal 
model to date is able to fully recapitulate all attributes of 
the disease seen in humans (15). As a result, further 
studies of gut-liver interactions are restricted and this 
impacts on our understanding of the disease and our 
ability to develop potential treatments. In order to 
determine if the lower gut-liver axis (colon-microbiome-
immune interactions) drives the disease activity in PSC, 
the aim of this systematic review was to determine if 
total colectomy had any effect on the progression of 
PSC.   
 
Methods 
Literature search 
The systematic review was performed following 
standard PRISMA guidelines (16). A search of Medline, 
Cochrane, and Scopus databases was performed for 
articles containing the terms "colectomy" AND "primary 
sclerosing cholangitis" or “bowel resection” AND 
"primary sclerosing cholangitis" that were published up 
to April 2018. Unpublished literature was identified 
through the OpenGrey database. Additional studies that 
were not included in the database search were identified 
through searching the reference lists of retained articles. 
Inclusion and exclusion criteria 
All observational studies, except for case reports and 
small case series (less than five patients), were included 
for further evaluation when available. All patients with 
a confirmed diagnosis of PSC were included. Patients 
who had PSC but not undergone colectomy were used as 
a control group, and total colectomy or procto-
colectomy were considered as an identical intervention, 
where applicable. The exclusion criteria for meta-
analyses were: (i) studies that did not report sufficient 
primary data, (ii) studies with irrelevant content and (iii) 
studies that were not accessible by the UK Access 
Management Federation. 
Data extraction  
Two authors (JO and MFB) independently reviewed 
all titles and abstracts then assessed articles against the 
inclusion criteria for analysis. A third reviewer (YAN) 
resolved any differences. The primary outcome measure 
was the progression of PSC as determined by serological 
or histological evidence, defined pragmatically on the 
specific criteria used within each study. Secondary 
outcome measures were the rate of liver transplantation 
(including re-transplantation) or transjugular 
intrahepatic portosystemic shunts (TIPSS) when liver 
transplantation was unsuitable, and mortality rates. Data 
were extracted independently by authors JO and MFB 
using a standardized form. Data extracted included 
serological or histological progression of PSC, 
transplantation rates, and mortality rates. Quality of the 
studies included was assessed using a modified 
Newcastle–Ottawa Scale. 
Data synthesis and analysis 
Forest plots were used to illustrate effect size 
between studies, where possible. Each study included 
had an odds ratio (OR) with respective 95 percent 
confidence interval (CI) calculated. A Mantel-Haenszel 
(M-H) statistical method was performed, calculating an 
overall OR for respective outcomes: an OR less than 
1.00 inferred a worse survival for the colectomy group 
versus the control group, whilst an OR greater than 1.00 
inferred a better survival. The significance level was set 
to 5% for all tests and alternative hypotheses were two-
sided. High heterogeneity between studies was 
presumed and a random-effects model was used. A 
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funnel plot was employed to assess for potential 
publication bias (Appendix 1).  
All-cause mortality following colectomy was plotted for 
each study against respective mean study follow up. A 
mean-weighted linear regression was performed to 
estimate the change in all-cause mortality per year. 
Statistical analysis was performed using Review 
Manager (RevMan) Version 5.3 (Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 
2014) and GraphPad Prism 5.0 (GraphPad Software, La 
Jolla California USA). 
 
Results 
675 studies were identified from the initial literature 
search (Figure 1). Following removal of duplicates and 
abstract screening, twenty-four full-text articles were 
reviewed. After excluding articles with insufficient data 
(n=2), irrelevant content (n=5) and inaccessibility (n=2), 
a total of fifteen articles were included in the final review 
(8-28). 
Rate of PSC Progression 
Overall, colectomy did not appear to have an effect on 
PSC progression. Two studies directly comparing patients 
with PSC following colectomy versus no colectomy were 
Figure 1. Systematic review flow diagram 
 
identified (Table 1) but there was no significant difference 
between both groups of patients. No randomized control 
trials were identified; the limited number of studies 
identified precluded additional quantitative analysis. 
 
Table 1. PSC progression rates in patients with colonic disease, with and without colectomy  
Study, Year Type of 
Resection 
Follow-
up 
(years) 
Sample size in study No change to PSC activity or PSC 
progression 
Colectomy, 
n 
No Colectomy, 
n 
Colectomy,  
n (%) 
No Colectomy,  
n (%) 
Cangemi et al, 1989 (8) PC 3 13 17 13 (100%) 17 (100%) 
Alabraba et al,2009 (14) PC or CO 6.9 46 169 15 (32.6%) 39 (23.1%) 
Aitola et al, 1994 (17) PC or CO 4.8 7 * 5 (71.4%) * 
Mikkola et al, 1995 (18) PC or Co 9 13 * 4 (30.8%) * 
Goudet et al, 2000 (9) PC or CIA 10 36 * 18 (50.0%) * 
Cho et al, 2008 (19) IPA 4.3 22 * 2 (9.1%) * 
Lepisto et al, 2009 (20) PC, IPA 11 30 * 15 (50%) * 
PC = Proctocolectomy, Co = Colectomy, IPA = Ileal pouch-anal canal anastomosis, CIA = Colectomy with ileorectal anastomosis, * = no control 
group in study 
 
Table 2. Liver transplantation or TIPSS rates in patients with colonic disease, with and without colectomy 
Study, Year Type of 
Resection 
Follow-
up 
(years) 
Sample size in study Transplantation or TIPSS 
Colectomy, 
n 
No 
Colectomy, n 
Colectomy, 
n (%) 
No 
Colectomy, 
n (%) 
Poritz et al, 2003 (21) PC or Co 7 16 6 6 (37.5%) * 
Navaneethan et al, 2011 (22) PC, PBI, or IPA 13.4 92 75 30 (32.6%) 56 (74.7%) 
Nordenvall et al, 2018 (23) Co or SR 5.9 477 2092 51 (10.7%) 276 (13.2%) 
Lepisto et al, 2009 (20) PC 11 30 * 15 (50%) * 
Mathis et al, 2012 (24) PC 5.9 100 * 9 (9%) * 
Lian et al, 2012 (25) Co 15 23 * 9 (39.1%) * 
OLTx = Liver Transplant, PC = Proctocolectomy, Co = Colectomy, SR = Segmental large bowel resection, IPA = Ileal pouch-anal canal 
anastomosis, PBI = proctocolectomy with Brooke’s ileostomy, * = no control group in study 
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Figure 2. Forest Plot-Effect of colectomy on liver transplantation 
of TIPSS in PSC patients 
 
Figure 3. Linear regression of mortality following colectomy; 
gradient 2.11, p= 0.032 R2=0.722 
 
One study (8) followed up 30 patients in total over 3 years 
follow-up, reporting disease progression in all patients, 
both colectomy and non-colectomy. Another study (14) 
reported data on 46 patients who had undergone a 
colectomy and 169 patients as the control, for an average 
follow-up of 6.9 years, and noted PSC progression rates as 
32.6% and 23.1% respectively (p=0.19). 
Five further observational studies were identified with a 
follow-up period ranging between 4.3 to 11 years (9, 17-
20). However, these studies did not have control groups 
so statistical comparisons were not possible. The 
reported PSC progression rates ranged between 9.1% 
and 50%.  Due to heterogeneity in the definitions of PSC 
progression used in the studies, linear regression 
analysis was not attempted. 
Rates of Liver Transplantation or TIPSS  
Six studies (20-25) reporting liver transplantation 
rates (or TIPSS in cases where liver transplantation was 
unsuitable) were included (Table 2). Follow-up ranged 
from 5.9 to 13.4 years, with rates reported between 9% 
and 50%. Three studies (21-23) directly compared 
colectomy versus no colectomy in this patient cohort. 
Following forest plot analysis, no significant effect of 
colectomy on either the rates of liver transplantation or 
TIPSS was demonstrated (OR 0.59, 95% CI 0.14-2.53, 
p=0.48) (Figure 2).  
All-Cause Mortality Rates  
Seven studies were identified that reported all-cause 
mortality rates following colectomy (8, 23, 25-29) 
(Table 3). Mean-weighted linear regression analysis 
(Figure 3) demonstrated a 2.11% per year mortality risk 
(CI 0.03% to 4.18%, p=0.032 R2 = 0.722) for patients 
with PSC who have undergone colectomy. 
Two studies (8, 23) directly compared colectomy versus 
no colectomy group in PSC patients. One study (8) 
followed up 30 patients for 3 years and demonstrated 
similar mortality between the two groups, with rates of 
15.3% and 11.8% respectively. The other study (23) 
identified, followed 2569 patients for a median time of 
5.9 years, and also showed no difference in mortality 
rates for all time points of colectomy, reporting 17.4% 
versus 20.4% respectively. 
 
Table 3. Studies reporting mortality rates in PSC patients with colonic disease, with and without colectomy 
Study, Year Type of 
Resection 
Follow-up 
(years) 
Sample size in study Mortality Rates 
Colectomy, 
n 
No Colectomy, 
n 
Colectomy, 
n (%) 
No Colectomy, 
n (%) 
Cangemi et al, 1989 [8] PC 3 13 17 2 (15.3%) 2 (11.8%) 
Nordenvall et al, 2018 [23] Co 5.9 477 2092 83 (17.4%) 426 (20.4%) 
Post et al, 1994 [26] PC, Co 0.1 24 * 3 (12.5%) * 
Penna et al, 1996 [27] IPA 4.5 54 * 6 (11.1%) * 
Gorgun et al, 2005 [28] IPA 5 65 * 16 (24.6%) * 
Lian et al, 2012 [25] Co 15 23 * 8 (34.8%) * 
Treeprasertsuk et al, 2013 29] Co 5.5 78 * 13 (16.7%) * 
PC = Proctocolectomy, Co = Colectomy, IPA = Ileal pouch-anal canal anastomosis, * = no control group in study 
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Discussion 
Our results suggest that cumulatively there is limited 
evidence in the current literature to demonstrate any 
beneficial effect of colectomy on the disease activity of 
PSC. Nordenvall et al (23) reported that colectomy 
before the diagnosis of PSC was associated with lower 
liver transplantation and death rates in IBD-PSC patients 
and no effect was observed if colectomy was performed 
after PSC was diagnosed. Though interesting, these 
findings contradict a study by Alabraba et al (14) which 
reported that colectomy before or during liver 
transplantation for PSC significantly reduced PSC 
recurrence and liver re-transplantation rates. However, 
both the numbers in these specific subgroups were sub-
optimal. Taking into consideration that there is a lack of 
an established scientific mechanism through which these 
effects are achieved, an argument that these observations 
are due to chance alone could also be made. 
We were able to calculate an estimated mortality rate, 
based on the included studies, for patients with PSC 
following colectomy at 2.11% per year. Putting this into 
context, mortality rates for all PSC patients reported in 
the literature ranges between 3.3-5.8% (35-39), and 
whilst our data may therefore suggest a lower mortality 
rate post-colectomy, the heterogeneity and low quality 
in the studies included precludes any definitive 
conclusions to be drawn. In considering the above, 
together with the lack of robust evidence, we believe 
colectomy should not be offered as a treatment option 
for severe PSC until better patient studies or scientific 
advances are able to demonstrate otherwise. 
The main limitation of this systematic review was the 
lack of high-quality studies for meta-analyses in current 
literature. No randomized control trials were identified 
and only a small proportion of studies had a control 
group so that an effect size could be estimated. Another 
limitation was the high heterogeneity between studies, 
which was in part due to varying criteria of how disease 
progression was measured and defined within these 
studies. In this regard, it precluded meaningful 
quantitative analyses in this systematic review. Lastly, 
though the statistical analyses performed herein were 
robust, effects from small sample sizes in the meta-
analyses and publication bias cannot be excluded 
completely. Nonetheless, the main aim of this systematic 
review was to study PSC activity after the interference 
of the lower gut-liver axis is achieved through a 
"surgical knock-out" of the colon in humans.  
As animal models remain sub-optimal, observational 
studies such as case-control and association studies, 
although do not demonstrate causality, still provide 
important information and have contributed too much of 
our understanding of PSC (3). However, even in 
reviewing clinical studies of PSC in recent literature, it 
seems the role of the colon in the pathogenesis of PSC 
remains poorly understood and the chasm between basic 
sciences and clinical observations remain wide and 
poorly bridged. Invariably, this is reflected in the limited 
treatment options in clinical practice. It is also 
noteworthy that although well designed longitudinal 
studies could offer alternative means to identify 
causative microorganisms, the lack of a reliable 
biomarker in early disease, low prevalence of the 
disease, and poor accessibility of the biliary tree restrict 
the conduct of these studies (15).  
Moving away from animal models and clinical 
observational studies, in vitro longitudinal and high 
throughput screens of the microbiome in the lower GI 
tract offers the possibility of identifying the pathogenic 
microorganisms in PSC as the cost of interrogating the 
microbiome becomes more affordable. Unfortunately, 
even if a pathogen is identified, the transition from 
mechanistic studies to identify a target for drug action 
and then to drug safety studies preclude the use of any 
pharmacological treatments in the near future. In 
considering novel and potential treatments for PSC that 
are on the horizon, faecal transplantation is perhaps the 
closest at being introduced into clinical practice. Fecal 
transplantation could potentially reverse gut dysbiosis in 
PSC and provide a means of controlling PSC 
progression where current drug treatments have failed. 
Interestingly, a clinical trial assessing the effects of 
faecal transplantation in patients with PSC is currently 
in progress (ClinicalTrials.gov, Identifier: 
NCT02424175) and the results of this study are eagerly 
awaited. Alternatively, advances in regenerative 
medicine (40,41) have made considerable progress in 
our understanding of cholangiocyte biology. In vivo 
studies and transplantation of lab-grown bile ducts are 
being undertaken in porcine models which could 
potentially be used in the treatment of large duct PSC 
(University of Cambridge, UK).  
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In summary, the colon as part of the lower gut-liver axis 
is likely to be involved in the pathogenesis of PSC but is 
unlikely to be the key factor driving the disease and 
higher-quality larger clinical trials are required. The 
pathogenic microbiome or antigens could potentially be 
identified in the midgut, since total colectomy has shown 
little effect on PSC activity. Though our understanding 
of the immune-mediated disease remains poor, rapid 
advances in regenerative medicine, high throughput 
screening of the gut microbiome, and research targeting 
the gut-liver axis are likely to make headway in 
developing new treatments for the disease. 
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Appendix 1. Funnel plot for studies induced in liver transplantation and TIPSS rate 
